General Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

Similar documents
General concepts in the Ph. Eur.: theory and rationale

Topics covered by the talk

Public Assessment Report. Scientific discussion. Pentasa Compact 4 g, prolonged-release granules. (mesalazine) NL License RVG:

Type II variation. Public Assessment Report for the suspension of. Palfium 5 mg tablets. (dextromoramide) NL License RVG: 03170

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) DRAFT (12/08) POINTS TO CONSIDER ON STABILITY TESTING OF HOMEOPATHIC MEDICINAL PRODUCTS

Guideline on quality of herbal medicinal products 2 /traditional herbal medicinal products

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use

Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1

IPEC Europe Suggested Alternative (if none then original text is clear and needs no alteration) Purpose and Scope

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004

General Chapter/Section: <232> Elemental Impurities - Limits Expert Committee(s): General Chapters Chemical Analysis No.

GUIDE TO REGISTER HOMEOPATHIC PRODUCTS FOR VETERINARY USE

Public Assessment Report. Scientific discussion. Rizatriptan Apotex disper 5 mg and 10 mg, orodispersible tablets. (rizatriptan benzoate)

REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.

Requirements to the Registration of Medicinal products in the Republic of Armenia

Public Assessment Report Scientific discussion. Modafinil Bluefish (modafinil) SE/H/1325/01/DC

Ciprofloxacin Bluefish (Ciprofloxacin hydrochloride)

Dr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013

Public Assessment Report Scientific discussion. Losartan/Hydrochlorothiazide Bluefish (losartan/hydrochlorothiazide) SE/H/780/01-02/DC

Guideline on quality of herbal medicinal products 1 /traditional herbal medicinal products

Guide to Registration of Homeopathic Veterinary Medicinal Products

(Adopted by the Committee of Ministers on 19 January 2011 at the 1103rd meeting of the Ministers Deputies)

Public Assessment Report. Scientific discussion. Granon (Acetylcysteine) DK/H/2352/ /MR. Date:

Overview of USP General Chapters <476> and <1086> Prescription/Non-Prescription Stakeholder Forum October 19, 2017

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use

AD HOC WORKING GROUP ON HERBAL MEDICINAL PRODUCTS

Public Assessment Report Scientific discussion. Oxikodon Depot Actavis (oxycodone hydrochloride) SE/H/1313/01-08/DC

Public Assessment Report. Scientific discussion. Acetylcysteine YES 600 mg, effervescent tablets. (acetylcysteine) NL/H/2975/001/DC

LIQUID PREPARATIONS FOR ORAL USE. Final text for addition to The International Pharmacopoeia (November 2007)

Public Assessment Report. Scientific discussion. Mogilarta. (Telmisartan and hydrochlorothiazide) DK/H/2306/ /DC.

Public Assessment Report Scientific discussion. Lamotrigin Medartuum Lamotrigine SE/H/728/01-04/MR

Decentralised Procedure. Public Assessment Report. Lorazepam-neuraxpharm 1/ 2,5 mg Schmelztabletten. Lorazepam DE/H/4558/ /DC

The International Pharmacopoeia - Overview

MEDICNES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF HERBAL MEDICINAL PRODUCTS IN THE GAMBIA

Dormeasan, oral drops, solution (Valeriana officinalis L., radix, tincture; Humulus lupulus L., strobulus, tincture)

Excipient Risk Assessment

Good pharmacopoeial practices: Chapter on monographs on herbal medicines

IMPORTANT DISCLAIMER. Note

Discussion at the HMPC January March Draft agreed by Quality Working Party April Adoption by CHMP for release for consultation 26 May 2005

Public Assessment Report. Scientific discussion. Acetylsalicylzuur Disphar 500 mg and 1000 mg, oral powder. (acetylsalicylic acid)

Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1

Eprosartan 300 mg, 400 mg and 600 mg Film-coated Tablets. (Eprosartan mesilate) PL 37222/

Health Products Regulatory Authority IPAR. Public Assessment Report for a. Traditional Herbal Medicinal Product

Public Assessment Report Scientific discussion

Adopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017

Public Assessment Report Scientific discussion. Eezeneo (Diclofenac potassium) Asp. no:

Decentralised Procedure. Public Assessment Report. Metamizol Midas / Metamizol STADA / Mimetanal 500 mg Tabletten. Metamizole sodium monohydrate

QUALITY OF HERBAL MEDICINAL PRODUCTS: PRESENT REQUIREMENTS

Vol. 41(1) [Jan. Feb. 2015] (P) \\uspnetapp2\share\share\uspnf\printq\pager\xmlin\lyc_ _m99989.xml. Nov.

Public Assessment Report. Scientific discussion. Levofloxacin Bluefish (levofloxacin hemihydrate) SE/H/889/01-02/DC

Expectations for Implementation in Europe

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009

Public Assessment Report. Scientific discussion. Ipratropiumbromide/Salbutamol Cipla 0.5 mg/2.5 mg per 2.5 ml, nebuliser solution

Public Assessment Report. Scientific discussion. Lorazepam GenRx 1 mg and 2.5 mg tablets. (lorazepam) NL/H/3485/ /DC

AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION. (Moscow, 23 December 2014)

QUALITY OF HERBAL REMEDIES

H e r b a l M e dicines' Q U A L I T Y M ANUAL. I. Introduction

Public Assessment Report. Scientific discussion. Citalopram Jubilant 10 mg, 20 mg, 30 mg and 40 mg, film-coated tablets.

EUR-Lex L EN. Council Directive 93/74/EEC of 13 September 1993 on feedingstuffs intended for particular nutritional purposes

C 178/2 Official Journal of the European Union

quality and safety of pharmacy preparations in Europe

Guidance notes on the classification of food extracts with colouring properties Last update [ ]

Public Assessment Report Scientific discussion. Rizatriptan Orifarm (rizatriptan) SE/H/1104/01-02/DC

Public Assessment Report Scientific discussion

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL PROCEDURE FOR THE PREPARATION OF COMMUNITY MONOGRAPHS FOR TRADITIONAL HERBAL MEDICINAL PRODUCTS

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

Public Assessment Report Scientific discussion

Public Assessment Report Scientific discussion. Anastrozole Bluefish 1 mg film-coated tablets (anastrozole) SE/H/781/01/DC

Practical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings

Public Assessment Report Scientific discussion. Ciprofloxacin Accord (ciprofloxacin hydrochloride) SE/H/1026/01-03/DC

Public Assessment Report Scientific discussion. Quetiapin Orion (quetiapine fumarate) SE/H/1115/01-04/DC

Public Assessment Report for a Homeopathic Medicinal Product for Human Use

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Public Assessment Report Scientific discussion

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use

Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use

Decentralised Procedure. Public Assessment Report. ALGOTRA 37.5 mg/325 mg überzogene Tabletten Tramadol/Paracetamol DE/H/3688/001/DC

Public Assessment Report. Scientific discussion. Tadalafil 1A Pharma 2.5 mg, 5 mg, 10 mg and 20 mg, film-coated tablets.

Public Assessment Report Scientific discussion. Ginsana, oral solution. Asp.no.:

Organic Impurities in Drug Substances and Drug Products. Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 8, 2017

Public Assessment Report Scientific discussion. Dexametason Abcur Dexamethasone SE/H/1260/01-02/DC

Excipient Functionality & Pharmacopoeia IPEC Europe Excipients Forum Nice, 5 February 2015

SCIENTIFIC DISCUSSION

Draft Guidance for Pharmacists on Extemporaneous Dispensing. Version 1

Checklist of issues to be considered by food business operators when implementing Commission Regulation (EC) No 2073/2005

COMMISSION REGULATION (EU)

Public Assessment Report Scientific discussion

Guidance for Pharmacists on Extemporaneous Dispensing

Public Assessment Report. Scientific discussion. Carvedilol Aurobindo 6.25 mg and 25 mg, film-coated tablets (carvedilol) NL/H/2609/ /MR

USP Perspective on Atypical Actives November 29, 2017

Residual Solvents: FDA/ Regulatory Perspective

Public Assessment Report Scientific discussion. Oxikodon Actavis (oxycodone hydrochloride) SE/H/1226/01-03/DC

Public Assessment Report Scientific discussion. Sumatriptan Pfizer (sumatriptan succinate) SE/H/973/01-02/DC

EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS

PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LIQUID PREPARATIONS FOR ORAL USE

Public Assessment Report Scientific discussion

Public Assessment Report. Scientific discussion. Thyrofix 25, 50, 75 and 100 micrograms tablets. (levothyroxine sodium) NL/H/3039/ /DC

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Transcription:

General Concepts in the European Pharmacopoeia Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

General notices Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 1

General Notices Put at the very beginning of the Ph. Eur. (page 1), they address general issues and are aimed at providing the basic information to the user Apply to all texts Rules to understand texts, conventional expressions Essential reading before starting to use monographs Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 2

Typical questions that are answered in the General Notices Do specifications apply throughout shelf-life? Are alternative methods allowed? The monograph specifies 1.000 g to be weighed for the test, what is the tolerance? Is Solubility a mandatory requirement? Is the Second Identification compulsory? Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 3

Alternative methods Ph. Eur. tests are reference methods, essential in cases of dispute Compliance is required, but alternative methods may be used as long as they lead to the same pass/fail result. It is the responsibility of the user to demonstrate their suitability. Approval of the competent authority is necessary in many cases. Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 4

Waiving of tests In some cases some tests may be omitted based on validation data or other suitable justification Tests for process-specific impurities may be omitted if it is demonstrated that they will not occur with the particular process used Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 5

Waiving of tests «The manufacturer may obtain assurance that a product is of Pharmacopoeia quality from data derived, for example, from validation studies of the manufacturing process and from in-process controls. Parametric release in circumstances deemed appropriate by the competent authority is thus not precluded by the need to comply with the Pharmacopoeia.» Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 6

Legal status of monographs Monographs are official standards Medicines legislation in Europe makes monographs obligatory standards (2001/83/EC, 2001/81/EC) Monographs may be accepted as suitable standards even when not obligatory Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 7

What does compliance mean? Compliance with a monograph: All mandatory parts of a monograph Compliance until time of use for raw materials Compliance throughout period of validity for preparations In-use compliance decided by licensing authority for each preparation Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 8

What must comply? What must comply? Mandatory for all substances for pharmaceutical use Ingredients (incl. excipients) of final formulation Components of solvents, buffers etc in or used to make up final formulation Solvents used for purification? If a monograph exists, then compliance will usually be required Reagents? Not usually needed for upstream use Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 9

Validation of Pharmacopoeial methods «The test methods given in monographs and general chapters have been validated in accordance with accepted scientific practice and current recommendations on analytical validation. Unless otherwise stated in the monograph or general chapter, validation of the test methods by the analyst is not required.» General Notices, 6th edition Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 10

Human and veterinary use Unless otherwise stated, monographs cover human and veterinary use Where a substance is used in both human and veterinary products, the same quality specification is applied When the monograph title bears for veterinary use the substance is intended only for veterinary products Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 11

General Chapters

Why general chapters? Analytical methods: Editorial convenience : avoid repeating standard methods in each monograph Provide standard methods that can be used where there is no monograph Give general requirements for equipment, equipment verification Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 13

General chapters General chapters Not mandatory per se When referred to in a monograph, they become part of the standard Can be used for substances not covered by monographs, may need validation Some general chapters are not referred to in any monograph (Raman spectrometry): useful guidance, can be referred to in applications Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 14

General chapters Many have validity or equipmentverification requirements These requirements become part of monograph Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 15

Chromatographic separation techniques 2.2.46. LC, SEC, GC, TLC and SFC System suitability: Peak symmetry Repeatability (for assays) Limit of quantification Adjustment of operating conditions Requirements apply wherever methods are prescribed in monographs Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 16

General chapters in section 5 not analytical methods 5.1 Preparation of sterile products / Microbiology 5.2 Production and QC of vaccines 5.3 Statistical Analysis 5.4 Residual solvents 5.9 Polymorphism 5.10 Control of impurities Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 17

General Monographs

Why general monographs? Two types: General monographs on classes of substances General monographs on dosage forms Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 19

General monographs Classes defined by different criteria: production method, origin, risk factors Aspects that cannot be treated in each individual monograph Residual solvents TSE/BSE Pesticides in herbals etc. Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 20

General monographs Apply to all relevant products No cross-reference in individual monographs CHECK WHICH GENERAL MONOGRAPHS APPLY! Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 21

Complementarity of General & individual monographs «General monographs and individual monographs are complementary. If the provisions of a general monograph do not apply to a particular product, this is expressly stated in the individual monograph.» General notices, 6th edition Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 22

General monographs on dosage forms Contain requirements common to all dosage forms of the type defined (tablets, capsules, parenteral preparations etc) Classified by pharmaceutical form/route of administration Applied during licensing Framework specification: acceptance criteria and extra tests are proposed by manufacturer and approved by competent authority Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 23

Specific monographs

Specific monographs Requirement for a substance consists of: Specific monograph + general monograph(s) Whole set of requirements defining quality Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 25

TITLE INNs used almost universally (modified to indicate salt) Titles now include degree of hydration Use in labelling required Molecular formula and mass: do not have to be checked! Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 26

DEFINITION Chemical nomenclature Assay limits LC assay: reflect assay variability and purity (eg:, 96.0-102.0% means 2% assay variability and 3.0% total impurities) Microbiological assay: minimum activity (IU/mg, as is) Biological assay: specific activity (eg: IU/mg) Solvent-free substance is implied even where not stated (see Substances for Pharmaceutical Use, residual solvents) Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 27

Scope May include statements on scope (eg route of synthesis) Monograph applies to all grades, unless otherwise stated Special grades may be mentioned in body of monograph (parenteral etc.) Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 28

Use of excipients Definition indicates where applicable that additives can be used (antioxidants, etc). See Substances for Pharmaceutical Use: Processing with addition of excipients is permitted only where this is specifically stated in the Definition of the individual monograph. Indication on the label Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 29

PRODUCTION SECTION Instructions to manufacturers May relate to source materials, manufacturing process, its validation and control or to inprocess testing Cannot necessarily be verified by independent analyst Compliance established by competent authorities -> e.g. by examination of data or inspection Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 30

CHARACTERS Not analytical requirements, do not have to be checked Useful information for the analyst (solubility, hygroscopicity) Polymorphism, where known, is mentioned (see also 5.9 Polymorphism) Physical properties may be mentioned (melting point, refractive index, density) Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 31

IDENTIFICATION First and Second identifications/alternative identifications: defined in General Notices First identification alone is always sufficient, Second is never mandatory Alternative identifications are equivalent Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 32

TESTS To detect: organic impurities, inorganic impurities, volatiles Methods: Physical and physico-chemical Chemical Chromatographic Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 33

Basis for impurities control Specifications and batch analysis data for approved products Specified impurities are those in specifications for approved products Specified impurities are qualified at or above the level indicated in the monograph Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 34

Template for requirements Limits for: Specified impurities Unspecified impurities Total impurities Impurities section Specified impurities Other detectable impurities If the Impurities section is not divided, all the impurities listed are specified Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 35

Other Detectable Impurities Specific Ph.Eur. category Impurities sections in monographs may have a list of ODIs Analytical information only: the impurity is detected by the monograph method ODIs are limited in the monograph by the limit for unspecified impurities (or Substances for Pharmaceutical Use) Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 36

IMPURITIES SECTION Gives impurities that are known to be detected by monograph tests Usually controlled by related substances test, but may be other tests Not necessarily exhaustive Based on information obtained and verified during elaboration Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 37

Directive 2003/63/EC However, where a starting material in the European Pharmacopoeia has been prepared by a method liable to leave impurities not controlled in the pharmacopoeia monograph, these impurities and their maximum tolerance limits must be declared and a suitable test procedure must be described. Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 38

Monograph revision Impurities control has to be updated for newly authorised products/sources: [Where] a monograph [may] be insufficient the competent authorities shall inform the European Pharmacopoeia. The marketing authorisation holder shall provide the European Pharmacopoeia with the details of the alleged insufficiency and the additional specifications applied. Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 39

Residual solvents Dealt with in Substances for Pharmaceutical Use and general chapter 5.4 Residual solvents Specific monographs do not include a test for residual solvents, except: Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 40

Residual solvents Class 1 solvents are always named and limited in monographs Class 3 solvents are only named and limited in monographs when they exceed 0.5% (impact on assay results) Class 2 solvents are NOT named and limited in monographs: chapter 5.4 applies Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 41

ASSAY Ph.Eur. policy prefers unspecific but precise assay (titration) provided related substances test is sufficiently characteristic and searching Well-defined salts: normally only the pharmacologically active part is determined by titration For chromatographic assays chapter 2.2.46 defines repeatability requirements Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 42

STORAGE Section is not mandatory Competent authority decides on storage - may decide to make Ph. Eur. mandatory Product has to be stored so as to ensure compliance with monograph Conventional expressions defined in General Notices Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 43

LABELLING Covered by national and international regulations Ph Eur indicates labelling items needed for application of monographs For example, nominal values (especially excipients) Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 44

LABELLING Labelling is interpreted in broad sense Not just what is read on container Information provided with the product is also included in labelling : package, leaflet, certificate of analysis Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 45

FUNCTIONALITY-RELATED CHARACTERISTICS Monographs on excipients Section is not mandatory Tests are linked to use (lubricant, filler, etc.) Section provides information on important parameters Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 46

Thank you for your attention! Anne-Sophie Bouin, 28/10/09 2009 EDQM, Council of Europe, All rights reserved 47